韩国新药的可获得性和预算影响:政策挑战和影响
Se-Eun Hwang1, Yoon-A Jang1, Kyung-Min Lim1
1College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Expert review of pharmacoeconomics & outcomes research
|March 31, 2025
概括
与美国,欧洲和日本相比,韩国药品支出有所控制,但新药的获取能力较低. 尽管支出高效,但新药拨款落后于国际基准.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 药物可访问性 药物可访问性
背景情况:
- 将韩国的新药获取能力与美国,欧洲和日本进行比较.
- 检查了韩国制药支出结构.
研究的目的:
- 评估韩国新药的患者可及性和预算影响.
- 为了将韩国新药的可获得性与主要国际市场进行比较.
主要方法:
- 分析了171种新药 (2013-2022) 的报销率和上市时间.
- 对226种新药 (2012-2021) 进行了预算影响分析,重点关注支出模式和风险分担协议.
- 进行了药物可访问性指标的国际比较.
主要成果:
- 在2013-2022年批准的新药中,67.8%的新药在2024年1月之前得到了补偿.
- 退款期限因药物类型和定价途径而异.
- 新药占医药总支出的8.5% (2012-2021年),其中瘤药物支出最高.
结论:
- 韩国有效地控制药品支出.
- 与美国,欧洲和日本相比,韩国对新药的拨款较低.
相关概念视频
Issues And Trends In Healthcare Delivery System
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


